Skip to main content

Fiscal Wizard · Single-issue tearsheet

APLS / Jun 21, 2026 Run #7393

APLS

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Composite verdict

B 73.9 / 100
Bullish setup · Reversal 10 drivers · 3 gates blocking
  • Volume Climax
  • Aroon Oscillator
  • Vortex Signal
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 26th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 17 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 52

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -96%
Asset value $2.89Earnings power value $4.40Price $41.03

Priced above its no-growth earnings power value ($4.40/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

47.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 100
Margin of Safety 0
Return on Capital Employed 83
OCF to Net Income 0
Return on Assets 83
Free Cash Flow Yield 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Volume Climax, Aroon Oscillator, Stochastic RSI); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Volume Climax 86
Aroon Oscillator 75
Vortex Signal 72

Risk Gates

3 blocking 7 caution

3 guards active, 24 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for APLS.